Genetic Susceptibility to Bladder Cancer

Status Recruiting

Clinical Trial Summary

This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

Clinical Trial Description

Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00848289
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact	Jian Gu, MD
Phone	713-792-3020
Email	jiangu@mdanderson.org
Status	Recruiting
Phase
Start date	February 10, 1998
Completion date	August 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06034015` - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers	Phase 1
Recruiting	`NCT04235764` - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed	`NCT02371447` - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT04081246` - Transurethral Modified En Bloc Resection For Large Bladder Tumours.	N/A
Recruiting	`NCT06059547` - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer	Phase 2
Terminated	`NCT04779489` - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer	N/A
Not yet recruiting	`NCT04493489` - Propranolol Adjuvant Treatment of Bladder Cancer	Phase 2
Completed	`NCT03520231` - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases	Phase 2
Recruiting	`NCT04537221` - Nordic Cystectomy Study III - Transfusion
Withdrawn	`NCT03007771` - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia	Phase 1
Completed	`NCT01955408` - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment	N/A
Completed	`NCT04487457` - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Recruiting	`NCT05562791` - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer	Phase 1
Completed	`NCT00199849` - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine	Phase 1
Completed	`NCT02781428` - To Detect the Sensitivity of the UroMark Assay
Recruiting	`NCT04738630` - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer	Phase 2
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Active, not recruiting	`NCT03978624` - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer	Phase 2
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A